Merck eyes $10B buyout of Verona Pharma - report

Sundry Photography/iStock Editorial via Getty Images

Merck (NYSE:MRK) is close to finalizing a deal worth around $10 billion to acquire Verona Pharma (NASDAQ:VRNA), a biotech firm specializing in lung diseases, according to a report by the Financial Times on Wednesday.

The deal would value Verona at $107